Product image of Mifegyne (Mifepristone) supplied by GNH India

Mifegyne

Active Ingredient:
Mifepristone
Origin:
EU

Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is an antiprogestogen (progesterone receptor antagonist) presented as a tablet for oral use. It blocks progesterone receptors, causing decidual breakdown and detachment of the embryo, and is used for the medical termination of intrauterine pregnancy up to 10 weeks in women.

GNH India supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Manufacturer / TM Owner

Exelgyn Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mifegyne (mifepristone) is used in the antiprogestogen pathway for early pregnancy termination.
  • Medical termination of intrauterine pregnancy up to 10 weeks: induces uterine lining breakdown and facilitates expulsion of the embryo when combined with misoprostol.

How It Works

  • Mifepristone acts as a competitive antagonist at progesterone receptors in the uterus and decidua. By blocking progesterone binding, it causes decidual breakdown, detachment of the embryo, and reduces expression of genes required for implantation. When followed by misoprostol, the drug enhances uterine contractility, completing evacuation of the gestational sac.

Side Effects

Mifegyne may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Abdominal pain or cramping
  • Vaginal bleeding or spotting
  • Nausea or vomiting
  • Diarrhea
  • Fatigue or weakness
  • Headache

Serious or Rare Side Effects

  • Heavy bleeding requiring transfusion
  • Severe infection (sepsis)
  • Allergic reaction including anaphylaxis
  • Incomplete abortion needing surgical intervention
  • Uterine rupture (very rare)
  • Liver injury or abnormal liver function tests

Precautions & Warnings

Before prescribing Mifegyne, clinicians should observe several safety precautions.

  • Confirm gestational age: ensure pregnancy is ≤10 weeks by ultrasound or reliable dating.
  • Exclude ectopic pregnancy: perform appropriate evaluation to rule out ectopic location.
  • Assess contraindications: avoid in patients with chronic adrenal failure, long‑term corticosteroid therapy, or anticoagulant use.
  • Obtain informed consent: discuss expected outcomes, possible side effects, and need for follow‑up.
  • Arrange follow‑up care: schedule clinical assessment and ultrasound to confirm complete evacuation.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Avoid Interactions

Mifegyne can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Systemic corticosteroids: may reduce effectiveness of mifepristone.
  • Anticoagulants (warfarin, DOACs): increase risk of severe bleeding.
  • Strong enzyme inducers (rifampin, carbamazepine): may lower plasma concentrations of mifepristone.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (ketoconazole, fluconazole): may increase mifepristone levels.
  • Antiepileptic drugs (phenytoin, carbamazepine): may modestly reduce drug exposure.
  • St. John’s wort or other herbal enzyme inducers: potential reduction in drug levels.

Frequently Asked Questions

Mifegyne is a brand name for the drug mifepristone and is used as part of a medical regimen to terminate an intrauterine pregnancy up to 10 weeks gestation. It works in combination with misoprostol to induce uterine contractions and expel the gestational tissue.

Mifepristone blocks progesterone receptors in the uterus and decidua, causing the lining to break down and the embryo to detach. This antagonism also sensitises the uterus to prostaglandins, so when misoprostol is given afterward, strong uterine contractions complete the abortion process.

The specific dose of Mifegyne is determined by the prescribing clinician based on national guidelines and the patient’s clinical situation. In most protocols a single oral tablet is administered, followed by misoprostol, but the exact regimen must be set by a qualified health professional.

Mifegyne is contraindicated in ongoing pregnancy beyond the intended termination and is classified as pregnancy category X. It should not be used by women who are breastfeeding because it may pass into breast milk and affect the infant.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Mifegyne‑based medical abortion is surgical evacuation. Medical abortion with mifepristone and misoprostol is non‑invasive, can be performed in outpatient settings, and avoids anesthesia, but it requires close follow‑up to confirm completeness, whereas surgical methods provide immediate removal.

Mifegyne tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Mifegyne is taken orally as a single tablet. After a prescribed interval, usually 24–48 hours, misoprostol is administered by the recommended route (often buccal, sublingual, or vaginal) to induce uterine contractions and complete the abortion.

Serious risks include heavy or uncontrolled bleeding that may require transfusion, severe infection (sepsis), incomplete abortion needing surgical intervention, and rare events such as uterine rupture or severe allergic reactions. Prompt medical attention is essential if any of these occur.

Mifegyne should not be used by women with confirmed ectopic pregnancy, chronic adrenal insufficiency, long‑term corticosteroid therapy, anticoagulant therapy, known hypersensitivity to mifepristone or misoprostol, or by anyone beyond 10 weeks gestation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mifepristone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT